Conference abstract · 12 Aug 2013
Conference abstractPublished 25 May 2017
Identification and validation of HLA-A24 XBP1, CD138, and CS1 peptides and induction of antigensspecific CD8+ T cell immunity using a multipeptide cocktail: Preclinical basis for vaccine therapy in HLA-A24 patients with
Dana-Farber Cancer Institute, USA Harvard Medical School, USA Boston University, USA Massachusetts General Hospital, USA VA Boston Healthcare System, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
XBP1 (X-box binding protein 1), CD138 (Syndecan-1) and CS1 (SLAMF7) are highly expressed antigens associated with tumor pathogenesis in cancers including multiple myeloma (MM) and various solid tumors. We have previously reported on the use of HLA-A2 peptides specific to these antigens to generate specific cytotoxic T cells (CTL). Vaccinations with these pooled peptides are currently in phase I/II clinical trials in patients with smoldering MM or triple negative breast cancer. The current studies extend this concept to the patients with HLA-A24, the second most dominant MHC-Class I in North America and the most common in Asia to broaden the patient population eligible for this cancer vaccine. Immunogenic HLA-A24 peptides derived from the antigens were evaluated. The identified XBP1 unspliced (UN)185-193 (I S P W I L A V L), XBP1 spliced (SP)223-231 (V Y P E G P S S L), CD138265-273 (I F A V C L V G F) and CS1240-248 (L F V L G L F L W) peptides were highly HLA-A24-specific and immunogenic, and induced ex vivo antigen-specific CTL with anti-MM activity in an HLA-A24 specific manner. Furthermore, a cocktail containing the four HLA-A24 peptides evoked MM-specific CTL with distinct phenotypic profiles (CD28, CD40L, 41BB, CD38, CD69) and antitumor activities, evidenced by perforin/CD107a/IFN-Ã?³/IL-2/TNF-Ã?± production induced by HLA-A24+ MM cells. The multipeptidespecific CTL included antigen-specific memory CD8+ T cell subsets expressing T cell activation and immune checkpoints antigens (CTLA, PD1, LAG3, TIM3). Treatment of the multipeptide-CTL with specific inhibitors against mTOR, AKT, HDAC6 or specific immune checkpoints enhanced frequency/activation of antigen-specific central memory CTL and their anti-tumor activity. These results highlight the potential therapeutic application of an HLA-A24 multipeptide vaccine to induce MM-specific CTL with a broad spectrum of anti-tumor activity, which may extend to solid tumors (breast, colon, and pancreatic cancer) expressing these antigens.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 2010
Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8 +T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii
Conference abstract
Concerns in the planning of therapeutic immunizations in HIV infected patients aiming to harness HLA E restricted CD8+T cell HIV suppressive activity
Conference abstract
The impact of HLA Class I on susceptibility to Hodgkin lymphoma is mediated by the magnitude of tumor associated CD8+ T-cell Immunity
Research article · 2015
Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3+CD8+ T cells against Various Solid Tumors
More from this journal
The newest in Cancer Science & Therapy.
Commentary · 21 Feb 2026
Functional Immune Biomarker Identification in Patients with Breast Cancer
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Jooeun Bae”
- BylineArticles whose byline prints “Derin Keskin”
- BylineArticles whose byline prints “Jun Zhou”
- BylineArticles whose byline prints “Guanglan Zhang”
- BylineArticles whose byline prints “Dharminder Chauhan”
- BylineArticles whose byline prints “Teru Hideshima”
- BylineArticles whose byline prints “Noopur Raje”
- BylineArticles whose byline prints “Paul Richardson”

